This Viewpoint examines how clinicians should approach amyloid-targeting therapies in patients with Alzheimer disease and suspected copathologies, emphasizing individualized decision-making, current e...

This longitudinal study develops and validates a blood plasma–based biological staging model for Alzheimer disease that closely mirrors an amyloid and tau positron emission tomography–based staging sy...

INTRODUCTION Usage of biomarker tests for Alzheimer's disease pathology and rates of positivity were assessed at the Washington University Memory Diagnostic Center. METHODS Patients who underwent ...

A quiet policy change means the government is making fewer bets on long-term science.

A visually engaging educational series for the practicing physician that distills complex concepts into concise, clinically relevant animations to enhance…

Nature Reviews Neurology, Published online: 03 November 2025; doi:10.1038/s41582-025-01154-yAdvances in biomarkers, blood tests and disease-modifying therapies have created a credible path to clinical prevention of Alzheimer disease (AD). In this Perspective, the authors discuss promising approaches to the prevention of AD and highlight strategic gaps.

Developed by Roche, this is the first blood test for use in primary care to rule out Alzheimer's-related amyloid pathology.

Halted training programs, funding chaos, and hiring freezes jeopardize advancement options for early career researchers.

Alzheimer's disease involves a drastic departure from the cognitive, functional, and behavioural trajectory of normal ageing, and is both a dreaded and highly prevalent cause of disability to individu...

Background: Unsupervised cognitive assessments are becoming commonly used in studies of aging and neurodegenerative diseases. Because assessments are completed in everyday environments and without a p...

Objective The objective of this study was to evaluate the timing of change of Alzheimer's disease (AD) plasma biomarkers (Aβ42/Aβ40, p-tau217, p-tau181, GFAP, and NfL) from six different assay platf.....

Diagnostic tests for Alzheimer disease can help guide clinical management, but results must be interpreted carefully.

Clinical trials for Alzheimer's disease (AD) must be registered on clinicaltrials.gov. The registry presents a variety of types of information related to the planned clinical trial. We assess clinic...

Genetic studies can offer powerful insights for the development of disease-modifying therapies for Alzheimer's disease. Protective genetic variants th…

More than 5,000 homes were impacted, and 38 people were injured after an EF3 tornado tore across St. Louis.

The emergence of monoclonal antibody (MABs) drugs since the FDA approval of lecanemab has resulted in dramatic changes in the clinical approach and management of early-stage Alzheimer’s disease (AD). ...

Listen to your favorite podcasts online, in your browser. Discover the world's most powerful podcast player.

Former National Institutes of Health Director Dr. Francis Collins, who abruptly left his NIH research lab in February, fears aggressive downsizing could impact Americans’ health.

A video from David Weisman, posted on Apr 17, 2025.

This cohort study investigates if the clinical phenotype of patients without dementia is associated with blood phosphorylated tau 217 interpretation.

Although valiltramiprosate failed to distinguish itself from placebo on the primary end point, the drug performed significantly better among mild MCI participants vs those with mild Alzheimer disease.

The test, which is not yet commercially available, focuses on a different form of the protein tau.

Alzheimer's Association statement: Actions taken by the Department of Health & Human Services may undermine the response to the dementia public health crisis.

Plasma eMTBR-tau243 is a specific biomarker of tau tangles in Alzheimer’s disease and enables the detecting and tracking of Alzheimer’s clinical impairment.

Plasma eMTBR-tau243 is a specific biomarker of tau tangles in Alzheimer’s disease and enables the detecting and tracking of Alzheimer’s clinical impairment.

Ending clinical trials with no warning can put patients at risk.

Donanemab (Kisunla®), an IgG1 monoclonal antibody targeting N-terminal pyroglutamate-modified forms of amyloid-β, is approved in the United States for…

Longstanding dementia cohorts, Alzheimer's Disease Research Centers in limbo

Prominent outside scientists who help the NIH evaluate its internal research programs are being abruptly removed